Björnsdóttir Erla, Janson Christer, Sigurdsson Jón F, Gehrman Philip, Perlis Michael, Juliusson Sigurdur, Arnardottir Erna S, Kuna Samuel T, Pack Allan I, Gislason Thorarinn, Benediktsdóttir Bryndis
Faculty of Medicine, University of Iceland, Reykjavík, Iceland ; Department of Respiratory Medicine and Sleep, Landspitali - The National University Hospital of Iceland.
Sleep. 2013 Dec 1;36(12):1901-9. doi: 10.5665/sleep.3226.
To assess the changes of insomnia symptoms among patients with obstructive sleep apnea (OSA) from starting treatment with positive airway pressure (PAP) to a 2-y follow-up.
Longitudinal cohort study.
Landspitali--The National University Hospital of Iceland.
There were 705 adults with OSA who were assessed prior to and 2 y after starting PAP treatment.
PAP treatment for OSA.
All patients underwent a medical examination along with a type 3 sleep study and answered questionnaires on health and sleep before and 2 y after starting PAP treatment. The change in prevalence of insomnia symptoms by subtype was assessed by questionnaire and compared between individuals who were using or not using PAP at follow-up. Symptoms of middle insomnia were most common at baseline and improved significantly among patients using PAP (from 59.4% to 30.7%, P < 0.001). Symptoms of initial insomnia tended to persist regardless of PAP treatment, and symptoms of late insomnia were more likely to improve among patients not using PAP. Patients with symptoms of initial and late insomnia at baseline were less likely to adhere to PAP (odds ratio [OR] 0.56, P = 0.007, and OR 0.53, P < 0.001, respectively).
Positive airway pressure treatment significantly reduced symptoms of middle insomnia. Symptoms of initial and late insomnia, however, tended to persist regardless of positive airway pressure treatment and had a negative effect on adherence. Targeted treatment for insomnia may be beneficial for patients with obstructive sleep apnea comorbid with insomnia and has the potential to positively affect adherence to positive airway pressure.
评估阻塞性睡眠呼吸暂停(OSA)患者从开始接受气道正压通气(PAP)治疗到随访2年期间失眠症状的变化。
纵向队列研究。
冰岛国家大学医院兰德spitali。
705名患有OSA的成年人在开始PAP治疗前和治疗2年后接受评估。
对OSA进行PAP治疗。
所有患者在开始PAP治疗前和治疗2年后均接受了医学检查以及3型睡眠研究,并回答了关于健康和睡眠的问卷。通过问卷评估失眠症状亚型的患病率变化,并在随访时使用或未使用PAP的个体之间进行比较。中度失眠症状在基线时最为常见,在使用PAP的患者中显著改善(从59.4%降至30.7%,P<0.001)。无论是否进行PAP治疗,初始失眠症状往往持续存在,而在未使用PAP的患者中,晚期失眠症状更有可能改善。基线时出现初始和晚期失眠症状的患者坚持使用PAP的可能性较小(优势比[OR]分别为0.56,P = 0.007和OR 0.53,P<0.001)。
气道正压通气治疗显著减轻了中度失眠症状。然而,无论是否进行气道正压通气治疗,初始和晚期失眠症状往往持续存在,并对依从性产生负面影响。针对失眠的针对性治疗可能对合并失眠的阻塞性睡眠呼吸暂停患者有益,并有可能对气道正压通气的依从性产生积极影响。